Beim europäischen Diabeteskongress in Lissabon sind mit DEPICT 1 und TANDEM 3 zwei Studien der Entwicklungsphase 3 zur SGLT-Hemmung bei Typ-1-Diabetes vorgestellt worden. Ihre Ergebnisse machen Hoffnung, bestätigen aber auch die Risiken.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Dandona P, Mathieu C, Phillip M Et al. Lancet Diabetes Endocrinol. 2017 Sep 13. pii: S2213-8587(17)30308-X. doi: 10.1016/S2213-8587(17)30308-X. [Epub ahead of print] Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Garg SK, Henry RR, Banks P et al. N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMoa1708337. [Epub ahead of print] Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Quellen
EASD-Symposien am 13. und 14.9.2017 in Lissabon; [1, 2]
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pampel, S.L. SGLT-Hemmung bei Typ-1-Diabetes quo vadis?. Info Diabetol 11, 44–47 (2017). https://doi.org/10.1007/s15034-017-1173-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15034-017-1173-4